You are here: Industry Insights > Bristol-Myers Squibb

News List

Could a patent dispute over Celgene MS hopeful ozanimod tank the BMS deal? fiercepharma
March 15, 2019
As if Bristol-Myers Squibb didn’t have enough to worry about, what with major investors trying to scuttle its $74 billion acquisition of Celgene, now a new concern has emerged—and it involves one of the six drug candidates that BMS executives have cited a
Bristol-Myers Squibb CEO insists proposed Celgene purchase not a "defensive deal" firstwordpharma
March 13, 2019
Bristol-Myers Squibb CEO Giovanni Caforio reiterated that the company's proposed $74-billion acquisition of Celgene is not designed to fend-off a takeover of the company. This "is not [a] defensive deal," Caforio said, as the drugmaker looks to persuade i
Bristol-Myers Squibb Announces Filing of Definitive Proxy Statement in Connection with Proposed Merger with Celgene firstwordpharma
February 23, 2019
The Bristol-Myers Squibb Special Meeting of Stockholders is scheduled to take place on April 12, 2019 at 10:00 a.m. Eastern Time.
Mirati Announces Collaboration with Bristol-Myers Squibb for Sitravatinib, OPDIVO Trial americanpharmaceuticalreview
January 09, 2019
Mirati Therapeutics announced a clinical collaboration with Bristol-Myers Squibb Company to evaluate the combination of sitravatinib and nivolumab (OPDIVO)....
Bristol-Myers Squibb to buy Celgene pharmatimes
January 08, 2019
Bristol-Myers Squibb has announced that it is to acquire Celgene, in order to “create a premier innovative biopharma company” and expand its cancer and immunotherapy offering.
Bristol-Myers Squibb to buy Celgene for around $74 billion firstwordpharma
January 03, 2019
Bristol-Myers Squibb entered an agreement to acquire Celgene under a cash and stock transaction with an equity value of approximately $74 billion, the companies announced Thursday.
Bristol-Myers Squibb Announces Offer from Taisho Pharmaceutical to Purchase UPSA americanpharmaceuticalreview
December 24, 2018
Bristol-Myers Squibb announced that Taisho Pharmaceutical has offered to purchase Bristol-Myers Squibb’s UPSA consumer health business for $1.6 billion....
Bristol-Myers Squibb and Boston Medical Center announce research collaboration to investigate markers of immuno-oncology response and resistance worldpharmanews
December 18, 2018
Bristol-Myers Squibb Company and Boston Medical Center announced a multi-year joint research study to identify and analyze potential sensitivity and resistance markers in patients treated with standard-of-care checkpoint inhibitors.
Vect-Horus, Amgen, Bristol-Myers Squibb pharmaceutical-technology
December 17, 2018
Vect-Horus has signed a research agreement with Janssen Pharmaceuticals for the development of neurodegenerative disease treatments.....
NICE backs use of Bristol-Myers Squibb's Opdivo via Cancer Drugs Fund for completely resected melanoma firstwordpharma
December 02, 2018
The National Institute for Health and Care Excellence issued a final appraisal document on Friday recommending use of Bristol-Myers Squibb's Opdivo (nivolumab) within the Cancer Drugs Fund (CDF) as an option for the adjuvant treatment of completely resect

Previous page 1 2 3 4 5 6 7 8 9 10 Next page